Compare Toronto-Dominion Bank (TD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs GeneDx Holdings Corp — how do they compare? Toronto-Dominion Bank trades at $115.1 (market cap $185.79B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Toronto-Dominion Bank is far larger — about 92× GeneDx Holdings Corp's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and GeneDx Holdings Corp for 19 Days on average.
| TD | WGS | |
|---|---|---|
Market Cap | $185.79B | $2.02B |
Volume | 3,263,867 | 734,640 |
Sector | Financials | Health |
52-Week High | $124.80 | $167.51 |
52-Week Low | $78.32 | $34.51 |
Typical Hold Time | 84 Days | 19 Days |
Enterprise Value | $559.06B | $2.05B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD Bank trades at $114.04, up 0.15% with a P/E of 17.36 and strong profitability metrics including 24.88% net income margin. Recent earnings have consistently beaten expectations, with three consecutive quarterly beats. Technical indicators show bearish momentum despite oversold RSI readings. The company announced a $10 billion share buyback program and $108 billion Canadian infrastructure commitment, signaling confidence in future growth.
The outlook remains positive with analyst consensus favoring Buy ratings (52.94%) and strong fundamentals, though technical weakness and increasing debt-to-asset ratios present near-term challenges. Revenue growth trajectory from $61.3B to projected $65.1B supports long-term investment case, while volatile cash flows require monitoring.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
